Funder
National Cancer Institute of the National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763.
2. SEER*Explorer: An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute; 2023 Apr 19. Updated 2023 Nov 16; cited 2024 Mar 27]. Available at: https://seer.cancer.gov/statistics-network/explorer/. Data source(s): SEER Incidence Data, November 2022 Submission (1975-2020), SEER 22 registries.
3. D’Angelica MI, Ellis RJ, Liu JB, et al. Piperacillin-tazobactam compared with cefoxitin as antimicrobial prophylaxis for pancreatoduodenectomy: a randomized clinical trial. JAMA. 2023;329(18):1579–88. https://doi.org/10.1001/jama.2023.5728.
4. Krell RW, McNeil LR, Yanala UR, Are C, Reames BN. Neoadjuvant therapy for pancreatic ductal adenocarcinoma: propensity-matched analysis of postoperative complications using ACS-NSQIP. Ann Surg Oncol. 2021;28(7):3810–22. https://doi.org/10.1245/s10434-020-09460-z.
5. Tzeng CW, Tran Cao HS, Lee JE, et al. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014;18(1):16-24; https://doi.org/10.1007/s11605-013-2412-1
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献